639VHomo sapiens (Human)Cancer cell line
Also known as: 639 V, 639-V, 639v, 639L (In PhosphoSite, due to an error in a patent.)
Quick Overview
Human bladder cancer cell line with TSC1 mutations and mTOR pathway activation.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_1048 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Ureter[UBERON:UBERON_0000056] |
Donor Information
| Age | 69 |
|---|---|
| Age Category | Adult |
| Sex | Male |
| Race | caucasian |
Disease Information
| Disease | Upper tract urothelial carcinoma |
|---|---|
| Lineage | Bladder/Urinary Tract |
| Subtype | Urethral Urothelial Carcinoma |
| OncoTree Code | UCU |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000973_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Arg248Gln (c.743G>A) | Unspecified | Somatic mutation acquired during proliferation | PubMed=20575032 |
| MutationSimple | TERT | c.1-124C>T (c.228C>T) (C228T) | Unspecified | In promoter | from parent cell line Hep-G2 |
| MutationSimple | PTEN | p.Arg173Cys (c.517C>T) | Homozygous | - | from parent cell line Reh |
| MutationSimple | PTEN | p.Arg130Gln (c.389G>A) | Heterozygous | - | Unknown, Unknown |
| MutationSimple | KRAS | p.Gly12Asp (c.35G>A) | Unspecified | - | PubMed=29786757 |
| MutationSimple | CDKN2A | p.Arg58Ter (c.172C>T) (p.Pro72Leu, c.215C>T) | Unspecified | - | PubMed=9598804 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Systematic review: characteristics and preclinical uses of bladder cancer cell lines.
Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.
Bladder Cancer 4:169-183(2018).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Erratum to: The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
Chanock S.J., Valencia A., Real F.X.
BMC Genomics 16:1019.1-1019.2(2015).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.
Chanock S.J., Valencia A., Real F.X.
BMC Genomics 16:403.1-403.16(2015).
Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
Knowles M.A.
PLoS ONE 8:E84411-E84411(2013).
Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.
Hurst C.D., Platt F.M., Knowles M.A.
Eur. Urol. 65:367-369(2014).
TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.
Kwiatkowski D.J.
J. Pathol. 230:17-27(2013).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes.
Stadler W.M., Olopade O.I.
Urol. Res. 24:239-244(1996).
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
Wright W.C., Daniels W.P., Fogh J.
J. Natl. Cancer Inst. 66:239-247(1981).
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
In vitro cultivation of epithelial cells derived from tumors of the human urinary tract.
Elliott A.Y., Bronson D.L., Stein N., Fraley E.E.
Cancer Res. 36:365-369(1976).
Transitional cell cancer: establishment and characterization of cell lines.
Elliott A.Y., Bronson D.L., Fraley E.E.
Natl. Cancer Inst. Monogr. 49:23-24(1978).
Cultivation, characterization, and identification of human tumor cells with emphasis on kidney, testis, and bladder tumors.
Fogh J.
Natl. Cancer Inst. Monogr. 49:5-9(1978).
Properties of cell lines established from transitional cell cancers of the human urinary tract.
Elliott A.Y., Bronson D.L., Cervenka J., Stein N., Fraley E.E.
Cancer Res. 37:1279-1289(1977).
Establishment and characterization of epithelial cell cultures from tumors of the human urinary tract.
Elliott A.Y., Bronson D.L., Cervenka J., Cleveland P.H., Fraley E.E.
(In book chapter) Cell culture and the application; Acton R. (eds.); pp.711-728; Academic Press; New York; USA (1977).